logo-loader
HealthPharma & Biotech
viewGenus plc

Genus upgraded by Kepler as African swine fever concerns abate

Kepler Chevreux analyst said that in the short term, it regards African swine fever as a manageable one-off that Genus can cope with

1544094766_shutterstock_714538813.jpg
Genus’s share price is 25% off the peak it reached last July

Genus PLC (LON:GNS) has been upgraded to a ‘buy’ from a ‘hold’ rating by broker Kepler Chevreux who believes the fall in the animal genetics company’s share price on the back of fears over the outbreak of African swine fever has been overdone.

Genus’s share price is 25% off the peak it reached last July, triggered by the outbreak of African swine fever (ASF) in China.

READ: Genus sounds note of caution over African swine fever and trade disputes

China accounts for 10% of earnings of Genus’ porcine division and for 15% of group earnings.

“In the short term, we regard African swine fever as a manageable one-off. Our base case assumes a 25% cut in PIC’s volume and EBIT in China in 2019E,” Kepler analysts said in a note to clients.

“We see the 25% decline in the share price as overdone and upgrade our rating from ‘hold’ to ‘buy’,” they added.

Kepler believes the fever will likely cause a modest slowdown in volume growth and a 1% cut in 2019 forecast earnings per share (EPS). In a worst-case scenario, another 5% cut in 2019E EPS might be needed, they add.

Shares in Genus were 8.2% up at 2,504.0p in late morning trade.

Quick facts: Genus plc

Price: 2956 GBX

LSE:GNS
Market: LSE
Market Cap: £1.92 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Primary Health Properties delivering 'impressive dividend track record and...

Proactive Research analyst Ed Stacey says Primary Health Properties (LON:PHP) has an impressive track record of dividend growth, increasing the payment every year since listing in 1997. On top of that he says they've delivered steady capital gains on its portfolio that have translated into...

5 hours, 38 minutes ago

2 min read